Search Results - "Minter, Ralph R"

Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency by Schindler, Christina, Collinson, Andie, Matthews, Carl, Pointon, Amy, Jenkinson, Lesley, Minter, Ralph R, Vaughan, Tristan J, Tigue, Natalie J

“…Doxorubicin is a chemotherapeutic agent that is commonly used to treat a broad range of cancers. However, significant cardiotoxicity, associated with prolonged…”
Get full text

Engineering therapeutic proteins for cell entry: the natural approach by Guillard, Sandrine, Minter, Ralph R, Jackson, Ronald H

“…Highlights • Toxins and viruses provide natural templates for the design of intracellular biologics. • Endosomal entrapment is a major issue for cytoplasmic…”
Get full text

A Shorter Route to Antibody Binders via Quantitative in vitro Bead-Display Screening and Consensus Analysis by Mankowska, Sylwia A., Gatti-Lafranconi, Pietro, Chodorge, Matthieu, Sridharan, Sudharsan, Minter, Ralph R., Hollfelder, Florian

“…Affinity panning of large libraries is a powerful tool to identify protein binders. However, panning rounds are followed by the tedious re-screening of the…”
Get full text

Targeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes by Taylor, Jonathan D., Barrett, Nathalie, Martinez Cuesta, Sergio, Cassidy, Katelyn, Pachl, Fiona, Dodgson, James, Patel, Radhika, Eriksson, Tuula M., Riley, Aidan, Burrell, Matthew, Bauer, Christin, Rees, D. Gareth, Cimbro, Raffaello, Zhang, Andrew X., Minter, Ralph R., Hunt, James, Legg, Sandrine

“…Proteins can be targeted for degradation by engineering biomolecules that direct them to the eukaryotic ubiquitination machinery. For instance, the fusion of…”
Get full text

Probing a Protein-Protein Interaction by in vitro Evolution by Thom, George, Cockroft, Alexis C., Buchanan, Andrew G., Candotti, Cathy Joberty, Cohen, E. Suzanne, Lowne, David, Monk, Phill, Shorrock-Hart, Celia P., Jermutus, Lutz, Minter, Ralph R.

“…In this study, we used in vitro protein evolution with ribosome and phage display to optimize the affinity of a human IL-13-neutralizing antibody, a…”
Get full text

In vitro evolution of antibody affinity via insertional scanning mutagenesis of an entire antibody variable region by Skamaki, Kalliopi, Emond, Stephane, Chodorge, Matthieu, Andrews, John, Rees, D. Gareth, Cannon, Daniel, Popovic, Bojana, Buchanan, Andrew, Minter, Ralph R., Hollfelder, Florian

“…We report a systematic combinatorial exploration of affinity enhancement of antibodies by insertions and deletions (InDels). Transposon-based introduction of…”
Get full text

Human monomeric antibody fragments to TRAIL-R1 and TRAIL-R2 that display potent in vitro agonism by Dobson, Claire L., Main, Sarah, Newton, Philip, Chodorge, Matthieu, Cadwallader, Karen, Humphreys, Robin C., Albert, Vivian, Vaughan, Tristan J., Minter, Ralph R., Edwards, Bryan M.

“…Apoptosis through the TRAIL receptor pathway can be induced via agonistic IgG to either TRAIL-R1 or TRAIL-R2. Here we describe the use of phage display to…”
Get full text

Phenotypic screening: the future of antibody discovery by Gonzalez-Munoz, Andrea L., Minter, Ralph R., Rust, Steven J.

“…•Phenotypic antibody screens against tumour cells and infectious agents are reviewed.•Hybridomas, combinatorial libraries and B cells provide antibodies for…”
Get full text

Phenotypic screening—the fast track to novel antibody discovery by Minter, Ralph R., Sandercock, Alan M., Rust, Steven J.

“…The majority of antibody therapeutics have been isolated from target-led drug discovery, where many years of target research preceded drug program initiation…”
Get full text

A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding by Douthwaite, Julie, Moisan, Jacques, Privezentzev, Cyril, Soskic, Blagoje, Sabbah, Shereen, Cohen, Suzanne, Collinson, Andie, England, Elizabeth, Huntington, Catherine, Kemp, Ben, Zhuang, Li, Hudak, Suzanne, Rees, D Gareth, Goldberg, Debbie, Barton, Chris, Chang, Linda, Vainshtein, Inna, Liang, Meina, Iciek, Laurie, Ambery, Philip, Peakman, Mark, Vaughan, Tristan J, Tree, Tim I M, Sansom, David M, Bowen, Michael A, Minter, Ralph R, Jermutus, Lutz

“…Affinity- and stability-engineered variants of CTLA4-Ig fusion molecules with enhanced pharmacokinetic profiles could yield improved therapies with the…”
Get full text

Harnessing phage and ribosome display for antibody optimisation by Dufner, Patrick, Jermutus, Lutz, Minter, Ralph R.

“…Therapeutic antibodies have become a major driving force for the biopharmaceutical industry; therefore, the discovery and development of safe and efficacious…”
Get full text

Correction: A CD80-Biased CTLA4-Ig Fusion Protein with Superior In Vivo Efficacy by Simultaneous Engineering of Affinity, Selectivity, Stability, and FcRn Binding by Douthwaite, Julie, Moisan, Jacques, Privezentzev, Cyril, Soskic, Blagoje, Sabbah, Shereen, Cohen, Suzanne, Collinson, Andie, England, Elizabeth, Huntington, Catherine, Kemp, Ben, Zhuang, Li, Hudak, Suzanne, Rees, D Gareth, Goldberg, Debbie, Barton, Chris, Chang, Linda, Vainshtein, Inna, Liang, Meina, Iciek, Laurie, Ambery, Philip, Peakman, Mark, Vaughan, Tristan J, Tree, Tim I M, Sansom, David M, Bowen, Michael A, Minter, Ralph R, Jermutus, Lutz

Get full text

Combinatorial Screening Identifies Novel Promiscuous Matrix Metalloproteinase Activities that Lead to Inhibition of the Therapeutic Target IL-13 by Urbach, Carole, Gordon, Nathaniel C., Strickland, Ian, Lowne, David, Joberty-Candotti, Cathy, May, Richard, Herath, Athula, Hijnen, DirkJan, Thijs, Judith L., Bruijnzeel-Koomen, Carla A., Minter, Ralph R., Hollfelder, Florian, Jermutus, Lutz

“…The practical realization of disease modulation by catalytic degradation of a therapeutic target protein suffers from the difficulty to identify candidate…”
Get full text

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator by Baker, Kevin P., Edwards, Bryan M., Main, Sarah H., Choi, Gil H., Wager, Ruth E., Halpern, Wendy G., Lappin, Patrick B., Riccobene, Todd, Abramian, Donara, Sekut, Les, Sturm, Bonnie, Poortman, Carol, Minter, Ralph R., Dobson, Claire L., Williams, Elizabeth, Carmen, Sara, Smith, Rodger, Roschke, Viktor, Hilbert, David M., Vaughan, Tristan J., Albert, Vivian R.

“…Objective To identify and characterize a fully human antibody directed against B lymphocyte stimulator (BLyS), a tumor necrosis factor–related cytokine that…”
Get full text

Cloning and characterization of Xenopus β2-microglobulin by Stewart, Rebecca, Ohta, Yuko, Minter, Ralph R., Gibbons, Terry, Horton, Trudy L., Ritchie, Pamela, Horton, John D., Flajnik, Martin F., Watson, Martin D.

“…cDNAs for Xenopus β2-microglobulin (β2m), the obligatory light chain of most vertebrate Major Histocompatibility Complex (MHC) class I molecules, were isolated…”
Get full text

Cloning and characterization of Xenopus beta2-microglobulin by Stewart, Rebecca, Ohta, Yuko, Minter, Ralph R, Gibbons, Terry, Horton, Trudy L, Ritchie, Pamela, Horton, John D, Flajnik, Martin F, Watson, Martin D

“…cDNAs for Xenopus beta2-microglobulin (beta2m), the obligatory light chain of most vertebrate Major Histocompatibility Complex (MHC) class I molecules, were…”
Get full text